Gremubamab
Based on 1 Customer Validation
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.40%
- CAS No.: 1800381-36-5
- Masse moléculaire:200.46 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
[VH-CH1-scFv-VH-VK-h-CH2-CH3_L-kappa]2
Pseudomonas aeruginosa
PcrV & PslG
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbits (acute pneumonia model)[2]
-
Dosage:1, 5, 15 mg/kg
-
Administration:I.v.; at 1 h postinfection
-
Result:Improved survival outcomes in a dose-dependent manner in a rabbit acute pneumonia model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[VH-CH1-scFv-VH-VK-h-CH2-CH3_L-kappa]2
ELISA, FACS, Functional assay
-
Immobilized Pseudomonas aeruginosa can bind Gremubamab. The EC50 for this effect is 136.6 ng/mL.
Chemical Information
-
CAS No. 1800381-36-5
-
Appearance Liquid
-
Masse moléculaire 200.46 kDa
-
Color Colorless to light yellow
-
SMILES
[Gremubamab]
-
Synonyms
MEDI3902
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. [Content Brief]
[2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gremubamab Related Classifications
HY-P99649 Related Classifications
Powered by Bioz